Miroslav Hájek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Miroslav Hájek has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Alžběta Kadlecová
Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic
1 shared publication- Anna Kertisová
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám.2, Prague 6, 16000, Czech Republic
1 shared publication Derek M. Huffman
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
1 shared publicationDominika Chalupská
Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic
1 shared publicationEma Chaloupecká
Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic
1 shared publicationEvzen Boura
Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 15 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (20) , eaeb7558
An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling
Insulin and insulin-like growth factors (IGF-1 and IGF-2) regulate metabolism, growth, and development via related receptors. In contexts such as brain function or fetal development, coordinated signaling by all three hormones is essential. We report the engineering of [GluB10, D-HisB24, GlyB31, TyrB32]-insulin ( 1 Ins ), an analog with high affinity for IR-A, IR-B, and especially IGF-1R. 1 Ins binds IGF-1R ~1000-fold more strongly than native insulin, approaching IGF-1 levels. Cryo–electron microscopy structures reveal how minimal substitutions in 1 Ins enable effective binding to both IR-A and IGF-1R. In neuronal cells, 1 Ins robustly activates both IR and IGF-1R pathways, promotes survival, and exceeds native ligands in neuroprotective assays. In vivo, 1 Ins regulates glucose effectively in mice and rats. Phosphoproteomic profiling confirms dual pathway activation and identifies targets specific to 1 Ins . These findings demonstrate that rational design of dual-receptor agonists can yield potent, versatile ligands with therapeutic promise in metabolic control, neuroprotection, and regeneration.
- 15 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (20) , eaeb7558
Open AccessAn engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling
Insulin and insulin-like growth factors (IGF-1 and IGF-2) regulate metabolism, growth, and development via related receptors. In contexts such as brain function or fetal development, coordinated signaling by all three hormones is essential. We report the engineering of [GluB10, D-HisB24, GlyB31, TyrB32]-insulin ( 1 Ins ), an analog with high affinity for IR-A, IR-B, and especially IGF-1R. 1 Ins binds IGF-1R ~1000-fold more strongly than native insulin, approaching IGF-1 levels. Cryo–electron microscopy structures reveal how minimal substitutions in 1 Ins enable effective binding to both IR-A and IGF-1R. In neuronal cells, 1 Ins robustly activates both IR and IGF-1R pathways, promotes survival, and exceeds native ligands in neuroprotective assays. In vivo, 1 Ins regulates glucose effectively in mice and rats. Phosphoproteomic profiling confirms dual pathway activation and identifies targets specific to 1 Ins . These findings demonstrate that rational design of dual-receptor agonists can yield potent, versatile ligands with therapeutic promise in metabolic control, neuroprotection, and regeneration.
- Open Access
A selective alternative pathway complement inhibitor for treatment of paroxysmal nocturnal hemoglobinuria
The complement system, a critical component of the human innate immune system, enhances the ability to clear microbes and damaged cells. Dysregulation of this system, particularly the alternative pathway (AP), can lead to several rare blood disorders such as paroxysmal nocturnal hemoglobinuria (PNH). This study introduces SH-01, a blood parasite-derived, novel recombinant protein which selectively inhibits the AP. We show that SH-01 effectively prevents the lysis of erythrocytes isolated from PNH patients. Unlike current treatments such as eculizumab, SH-01 targets the AP without impairing the classical or lectin pathways, reducing the risk of infections and extravascular hemolysis. SH-01 functions through a unique two-stage mechanism, preventing C3b deposition and inhibiting AP C5 convertase activity while maintaining the amplification loop’s functionality. Immunization studies in mice showed no significant immune response against SH-01, and the protein exhibited high stability and no acute toxicity. These findings suggest SH-01 as a promising candidate for treatment of PNH and other diseases characterized by AP hyperactivation, offering a more targeted therapeutic and thus safer approach.
Open AccessA selective alternative pathway complement inhibitor for treatment of paroxysmal nocturnal hemoglobinuria
The complement system, a critical component of the human innate immune system, enhances the ability to clear microbes and damaged cells. Dysregulation of this system, particularly the alternative pathway (AP), can lead to several rare blood disorders such as paroxysmal nocturnal hemoglobinuria (PNH). This study introduces SH-01, a blood parasite-derived, novel recombinant protein which selectively inhibits the AP. We show that SH-01 effectively prevents the lysis of erythrocytes isolated from PNH patients. Unlike current treatments such as eculizumab, SH-01 targets the AP without impairing the classical or lectin pathways, reducing the risk of infections and extravascular hemolysis. SH-01 functions through a unique two-stage mechanism, preventing C3b deposition and inhibiting AP C5 convertase activity while maintaining the amplification loop’s functionality. Immunization studies in mice showed no significant immune response against SH-01, and the protein exhibited high stability and no acute toxicity. These findings suggest SH-01 as a promising candidate for treatment of PNH and other diseases characterized by AP hyperactivation, offering a more targeted therapeutic and thus safer approach.
- Open Access
- 24 November 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 97, 129567
Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors
- 24 November 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 97, 129567
Open AccessDesign, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors
- Open Access
- 23 June 2021
- Published by BioResources in BioResources
- Vol. 16 (3) , 5601-5617
Processing of biomethane for electricity production as a sustainable way to treat municipal organic solid waste: A case study of the Corumbataí river basin region
This study proposed action scenarios for urban solid waste management in six municipalities in the Corumbataí River Basin. The operating scenarios were designed for organic waste treatment and for the shared disposal of urban solid waste. Six municipalities were studied, five of which had less than 30,000 inhabitants (Analândia, Charqueada, Corumbataí, Ipeúna, and Santa Gertrudes). In addition, Rio Claro had 199,000 inhabitants. Thus, the transport and transshipment stages, general infrastructure, and final disposal in landfills were analyzed. Further, the three scenarios for organic waste treatment were conducted separately. The items and the cost of implementation were estimated for decentralized composting, centralized composting, and biomethanization of waste with electricity recovery. The biomethanization scenario included the commercialization of electricity, so it generated revenues that decreased costs. This cost reduction was especially notable in the last years of the project when the goals of diversion of organic waste through selective collection were higher. The results suggested that the investigated scenarios could improve organic waste treatment and that the biomethanization scenario with electricity generation presented lower average costs per inhabitant than the centralized and decentralized composting scenarios.
- 23 June 2021
- Published by BioResources in BioResources
- Vol. 16 (3) , 5601-5617
Open AccessProcessing of biomethane for electricity production as a sustainable way to treat municipal organic solid waste: A case study of the Corumbataí river basin region
This study proposed action scenarios for urban solid waste management in six municipalities in the Corumbataí River Basin. The operating scenarios were designed for organic waste treatment and for the shared disposal of urban solid waste. Six municipalities were studied, five of which had less than 30,000 inhabitants (Analândia, Charqueada, Corumbataí, Ipeúna, and Santa Gertrudes). In addition, Rio Claro had 199,000 inhabitants. Thus, the transport and transshipment stages, general infrastructure, and final disposal in landfills were analyzed. Further, the three scenarios for organic waste treatment were conducted separately. The items and the cost of implementation were estimated for decentralized composting, centralized composting, and biomethanization of waste with electricity recovery. The biomethanization scenario included the commercialization of electricity, so it generated revenues that decreased costs. This cost reduction was especially notable in the last years of the project when the goals of diversion of organic waste through selective collection were higher. The results suggested that the investigated scenarios could improve organic waste treatment and that the biomethanization scenario with electricity generation presented lower average costs per inhabitant than the centralized and decentralized composting scenarios.